BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003;43:192-201. [DOI: 10.1046/j.1537-2995.2003.00280.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006;46:956-65. [DOI: 10.1111/j.1537-2995.2006.00828.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
2 Assal A, Py JY, Corbi C, Barlet V, Roubinet F, De Micco P. [Future technological evolutions in blood donation qualification]. Transfus Clin Biol 2007;14:132-41. [PMID: 17532244 DOI: 10.1016/j.tracli.2007.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Pereira A. Medidas de seguridad viral del plasma destinado a transfusión y su aplicación en España. Medicina Clínica 2007;129:458-68. [DOI: 10.1157/13111004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Fang C, Otero HJ, Greenberg D, Neumann PJ. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health. 2011;14:1010-1018. [PMID: 22152169 DOI: 10.1016/j.jval.2011.05.044] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
5 Teljeur C, Flattery M, Harrington P, O'neill M, Moran PS, Murphy L, Ryan M. Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland: COST-EFFECTIVENESS OF PRION FILTRATION. Transfusion 2012;52:2285-93. [DOI: 10.1111/j.1537-2995.2012.03637.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006;44:39-46. [PMID: 16168517 DOI: 10.1016/j.jhep.2005.06.016] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
7 Gessoni G, Barin P, Di Natale C, Marchiori G. NAT testing for HBV: the first routine application in Italy. Transfus Med 2004;14:385-6. [DOI: 10.1111/j.0958-7578.2004.00530.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 El-Ghitany EM, Farghaly AG, Hashish MH. Occult hepatitis B virus infection among hepatitis C virus seropositive and seronegative blood donors in Alexandria, Egypt. J Egypt Public Health Assoc. 2013;88:8-13. [PMID: 23528526 DOI: 10.1097/01.epx.0000422774.29308.b3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Gonzalez R, Echevarria JM, Avellon A, Barea L, Castro E. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion 2006;46:1138-42. [DOI: 10.1111/j.1537-2995.2006.00863.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
10 Borkent-raven BA, Janssen MP, van der Poel CL, Bonsel GJ, van Hout BA. Cost-effectiveness of additional blood screening tests in the Netherlands: COST-EFFECTIVENESS OF BLOOD SCREENING. Transfusion 2012;52:478-88. [DOI: 10.1111/j.1537-2995.2011.03319.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
11 Marshall DA, Kleinman SH, Wong JB, Aubuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004;86:28-40. [DOI: 10.1111/j.0042-9007.2004.00379.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 5.7] [Reference Citation Analysis]
12 Borkent-raven B, Janssen M, van der Poel C, de Wit G, Bonsel G, van Hout B. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009;49:311-9. [DOI: 10.1111/j.1537-2995.2008.01968.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
13 Custer B. Health Economics in Blood Safety. In: Shan H, Dodd RY, editors. Blood Safety. Cham: Springer International Publishing; 2019. pp. 53-81. [DOI: 10.1007/978-3-319-94436-4_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Samnaliev M, Tran CM, Sloan SR, Gasior I, Lightdale JR, Brustowicz RM. Economic evaluation of cell salvage in pediatric surgery. Paediatr Anaesth 2013;23:1027-34. [PMID: 23952976 DOI: 10.1111/pan.12233] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
15 Kuhns MC, Busch MP. New Strategies for Blood Donor Screening for Hepatitis B Virus: Nucleic Acid Testing versus Immunoassay Methods. Mol Diag Ther 2006;10:77-91. [DOI: 10.1007/bf03256447] [Cited by in Crossref: 64] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
16 Weber B, Mühlbacher A, Melchior W. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing. Journal of Clinical Virology 2005;32:67-70. [DOI: 10.1016/j.jcv.2004.09.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
17 Shang G, Seed CR, Wang F, Nie D, Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion. 2007;47:529-539. [PMID: 17319836 DOI: 10.1111/j.1537-2995.2006.01146.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.6] [Reference Citation Analysis]
18 Weber B, Van der Taelem-Brulé N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods. 2006;135:109-117. [PMID: 16567005 DOI: 10.1016/j.jviromet.2006.02.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
19 Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406-3417. [PMID: 19188662 DOI: 10.1182/blood-2008-10-167643] [Cited by in Crossref: 376] [Cited by in F6Publishing: 328] [Article Influence: 28.9] [Reference Citation Analysis]
20 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
21 Liu C, Chen D, Chen P. Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. Journal of Clinical Virology 2006;36:S33-44. [DOI: 10.1016/s1386-6532(06)80007-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
22 Almeida RP, Cardoso DD. Detection of HBV DNA by nested-PCR in a HBsAg and anti-HBc negative blood bank donor. J Clin Virol 2006;36:231-4. [PMID: 16574475 DOI: 10.1016/j.jcv.2006.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
23 Ringwald J, Mertz I, Zimmermann R, Weisbach V, Strasser E, Achenbach S, Seyboth S, Richter E, Eckstein R. Hepatitis B virus vaccination of blood donors--what costs may be expected? Transfus Med 2005;15:83-92. [PMID: 15859973 DOI: 10.1111/j.0958-7578.2005.00556.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
24 Kupek E. Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives. ISRN Infectious Diseases 2013;2013:1-15. [DOI: 10.5402/2013/839896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]